$ARK Innovation ETF(ARKK.US)$$Tesla(TSLA.US)$
Despite a year marked by underperformance, Wood is keeping pace with the disruptive innovation strategy that positioned her as a bull market poster child last year after her allocations to the so-called “stay-at-home” picks that benefited from COVID-19 lockdowns earned her an annual return of 150%. Even as those stocks fall out of favor, Wood, whose firm declined a request ...

$Advanced Micro Devices(AMD.US)$ Bounce on this will go crazy , all it takes is a 3-4% day

$SPDR S&P 500 ETF(SPY.US)$$iShares Core S&P 500 ETF(IVV.US)$$S&P 500 Index(.SPX.US)$
2022 will be a year of economic recovery and strong cyclical asset performance
Boosted by "strong profit growth" and the relief of supply chain difficulties. It is expected that international stocks, emerging markets and cyclical market sectors will perform significantly. However, in view of expectations of interest rate hikes and a slight tightening of monetary polic...

$Advanced Micro Devices(AMD.US)$ a lot of bearish sentiment market wide on the old twits. Market likes to do the opposite the next day. Guess we’re going green boys!

$NVIDIA(NVDA.US)$ still only seeing acquired shares from all kinds of firms. $310-320 should be a breeze tmr

$Advanced Micro Devices(AMD.US)$  Well at least CES is coming up on Tuesday. Semis could use a catalyst and that usually is a good trigger. Going to shelve the merger confirmation news for now since there is no indication about how much longer they need

$Tesla(TSLA.US)$ The US road safety regulator said that Tesla will recall more than 475,000 Model 3 and Model S electric vehicles to solve the rear-view camera and luggage problems, which will increase the risk of crashes. Tesla shares fell 3% in the morning, but then rebounded. The model years involved in this recall range from 2014 to 2021.

$Biogen(BIIB.US)$$SAMSUNG EL 144(SSNGY.US)$ The potential deal would mark Samsung Group's largest transaction since 2016, when the company bought U.S. electronics systems maker Harman for $8 billion.
The company's shares have fallen so far this year, dropping more than 30% in the past six months alone, despite the FDA approval of its Alzheimer's drug for marketing and regulatory victory in June.